It's a large segment of "unmarried women age 45 - 50" that have it. Between 50 - 70%. It's almost unbelievable - so don't take my word for it. Google it up and take the med site stats for yourself. So the market for a vaccine that actually works will be huge and ever growing. No matter how it's priced, it will account for a tidy revenue stream for the developer.
Those are the two I have on ignore; novasomes who was booted from the board for spamming, and his immediate reincarnation alter-idiot, spammerII or some such name. I ignored him immediately when I saw what he was doing, so I don't even remember his new name, but you know who I mean. Now watch him return under 10 more aliases to down vote me properly. Not worth talking about.
But the July 31st date IS worth talking about - because, in addition to the financial report, it also says they are going to announce "the details on independent and partnered development programs" later that same day in the conference call. The "independent" is very likely the Herpes II program, as they have said they are going it alone on that one. If it's positive news, the stock will go up to the next support level, and the action of this past week might be an indicator of short covering, since the short interest dropped dramatically this past month.
This is strictly wishful thinking in all likelihood, but they are announcing earnings "before" the open, rather than "after the close" which might be more good news about the bottom line at least - and since it was good last time, this might be a catalyst to recovery. If they announce good interim results in one of the trials during the CC, it might secure us for awhile.
I wonder, in light of the recent news release about the "price fixing" subpoena, if the SEC might take a fast peek into the very recent 100,000 share sell by Mr Hsu. Of course not. Nothing unusual about that.
Well, anyway we have the naughty satisfaction of knowing we are driving old NovaNuts bananas because he's on ignore…..post away, Nova! Post away!
Abstract dated June, 2013 - let's see if it will let me post the main info: this is promising in addition to the Herpes II application, it would surely seem.
Vaxfectin Adjuvant improves antibody responses to a DNA vaccine encoding the Measles virus
Yesterday the high volume continued as the price ascended. If the volume continues to rip as the pps inches up, it would seem to be a recovery. If short interest is getting wind of good interim trial results they could be the ones starting to cover, driving it up. the short interest fell last month and if this holds true, will fall again this month - all good signs if continued.
I do tend to agree after thinking it over. I saw this once myself when one of them (in much worse shape than this one) was dropped from the Russell 2000 but hadn't thought of it that way when this happened. Not short covering since the price didn't move upward, so not much else really makes sense so suddenly. Thanks for reminding me.
It was a strange day of volume with little sense other than the "rebalancing" suggestions posted here. I did see this happen once before, but the company was in much worse shape than VICL is - and did lose its Russell 2000 standing.
However, for every "sell" there is also a "buy" - which in this case suggests an "accumulation" of dumped shares by those buying, since there wasn't appreciable price increase. If it had been short covering, it would have driven the price up.
Watching these guys manipulate stock is one of the 7 Wonders of the World.
sweater pup: That is indeed a possibility and the right time, too. But I prefer to hope that it is accumulation of float by a few well placed sneak trades ahead of news. Of course, there isn't much info available to us peons that is current or meaningful, but from what I could determine, the float now is approximately 3 million less than it was during the month.
The "short interest" is down slightly for the month, too, (which is always a month old) but not enough to suggest short covering yet - UNLESS something spectacular has just happened behind the "closed door" between "them" and "us".
The latest short stats were released this morning. I'm trying to figure out how a share price can keep rising on "low" volume while the short interest keep rising too…..I just don't know….it's not computing to me.
couric - far be it from me to belittle a rising pps - I'm just having a hard time believing it will hold - because nothing is adding up to support a rise in price. The volume isn't all that large, and I checked the bid/ask sizes - bid 100, ask 300. These are small lots. Now, to my jaded mind, that isn't exactly something that should be pushing the price up.
I'm not biting yet.
Yes, the estimated completion date for the entire trial is July of next year - but I did think I read somewhere that the interim data is mid year this year and I thought July was mentioned then too.
It appears the trial is still recruiting.
The update data from the Herpes phase 1, 2 combo trial is due in mid year, which would put it any time now. I once read July but of course, that's just a teaser anyway. But if it's positive, it will give us the next leg up to recovery. The lack of rising short interest is another good sign, in my view. For now.
I agree totally about the long range prospects for IPXL. Probably the best thing they have going for them is that they are the last of the Generic drug companies. They too will be consumed at some point, and probably at a very nice premium.
My intent is to protect myself short term and buy back in if/when a large drop comes in view of these signals, and I could be wrong but I don't think so. There is not anywhere near enough volume right now to support the rise in the pps that is going on now - smells more like some manipulation and price supporting with small trades - and therefore doesn't support buying in more and playing with the sharks against the rapidly rising short interest.
My hunch is that the FDA is either going to give Hayward another list of insufficiencies to deal with or they are going to drag their feet on the re-inspection through this year - . A bright spot was the fact that they let the NDA go through rather than stopping it. But the bumps are not out of the road yet - in my opinion - after listening to the CC's as well as watching the shorts - and I'm content to wait for the downturn I feel has to come against what is sitting out there now.
Just hunches based on what I see as signals - which is all we get to work with playing in this sandbox. Good talking with you.
I looked at IDEX after your comment because such things interest me. I can't say as I see a parallel. The rise in short interest was much lower by increments over the months than has been IPXL's recent blast up. And the explosive rise in price of IDEX appears to be due to nothing more than the possibility of being bought out by Merck.
If you compare the stats (which are always a month behind for the benefit of us peons) you'll see IPXL had a FIVE million rise between March 31 and May 31 whereas IDEX has barely 1.5 million change over the same time period. Which is still noteworthy - and may indicate somebody out there thinks the Merck Deal may not be as solid as the stampede thought.
5/30/2014 20,048,562 956,000 20.971299
5/15/2014 19,779,105 924,791 21.387649
4/30/2014 18,990,083 870,770 21.808380
4/15/2014 18,892,375 1,806,293 10.459197
3/31/2014 18,566,072 1,618,434 11.471628
Interesting post, though, one worthy of a message board.
Just got a look at the latest short interest. The 4/30 jump was my cue to bail and sit it out for awhile.
5/30/2014 6,996,718 611,579 11.440416
5/15/2014 6,613,741 842,103 7.853839
4/30/2014 5,178,558 1,096,034 4.724815
4/15/2014 1,984,253 760,658 2.608601
3/31/2014 1,732,401 534,870 3.238920
Yes, and Yahoo doesn't do much to alleviate the situation. The ignore feature doesn't make the annoyer go away as it should, it simply fills up the board with thousands of greyed-out nonsense on the same posts saying you have ignored the user. Wow.